PsyIndex Weekly Update – April 19, 2021 – April 23, 2021

PsyIndex Weekly Update

April 19, 2021 – April 23, 2021
The PsyIndex rose more than 11% last week as most index components moved higher. The biggest industry news for the week was Mass General’s announcement that it was opening a new center to study psychedelics—a move showing just how mainstream psychedelics are becoming in medicine.

Market Performance

Weekly Performance: $129.12 (11.32%)

Powered by

CFN Enterprises Inc. (OTCQB: CNFN)

Top Gainers

Top Decliners

View All Index Constituents

Corporate News, Deals & Listings

  • Tryp Therapeutics (CSE: TRYP) reported key milestones for 2021, including its ongoing clinical development programs. Press Release
  • PharmaTher (CSE: PHRM) announced the submission of an IND application with the FDA for a Phase II clinical trial evaluating ketamine for the treatment of Parkinson’s disease. Press Release
  • Cybin (NEO: CYBN) demonstrated a proof of concept for its deuterated tryptamine for the treatment of depression and addiction. Press Release
  • Red Light Holland (CSE: TRIP) increased point of sale iMicrodose Packs in the Netherlands by more than 140%. Press Release
  • Silo Wellness (CSE: SILO) announced five new psychedelic wellness retreats in Jamaica. Press Release
  • Revive Therapeutics (CSE: RVV) announced successful results for its oral thin film psilocybin and filed U.S. provisional patent applications. Press Release
Read More

Featured Content

Microdosing: The Next Revolution in Psychedelics

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

We take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

Industry Developments

  • Massachusetts General Hospital launched a new center to study the neuroscience of psychedelics. via The Harvard Crimson
  • This billionaire took psychedelics, got Bitcoin and is now into SPACs. via Bloomberg Wealth
  • Psychedelics are quickly transforming the way that we understand depression and its treatments. via The Guardian
Visit the PsyIndex

Cannabis Law Report Has Been Publishing Legal, Professional & Regulated
Cannabis News Daily Since 2016 – All For Free

We want to carry on providing the important cannabis sector
news for free for all our readers.

Costs are rising to produce Cannabis Law Report and we’d like to ask you,
our readers, for a small donation.


Primary Sponsor

Cannabis Banking - FinCann

New: Free USA Cannabis Case Law Search – New Cases Daily

Directory Categories

Karma Koala Podcast

Sponsor – aBizinaBox

Top Marijuana Blog
%d bloggers like this: